EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

DNA Link Inc (127120) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of DNA Link Inc KRW 18,548, price KRW 31,800, upside -41.7%, quality 21 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7127120004

DL Thin data Sep 24, 2026

DNA Link Inc

127120 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 18,548 KRW · Strongly overvalued (−42%)
!Quality 21/100
!Mixed Growth (revenue 5y +4.8 %/yr)
!Loss-making · -77.6% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers (4/9)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch DNA Link Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

48,900 KRW 2,385 KRW Fair Value 18,548 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 2,385 KRW – 48,900 KRW · fair‑value band 12,245 KRW – 23,183 KRW · the 31,800 KRW price screens above the 18,548 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow DNA Link in your weekly email

Every Wednesday you see whether DNA Link is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally.

Show more

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In addition, it provides rare earth and permanent magnets. The company was formerly known as DNA Link, Inc. and changed its name to JS Link, Inc. in April 2025. JS Link, Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

Stock analysis

DNA Link Inc (127120) currently trades at 31,800 KRW, while our model-based Fair Value estimate is 18,548 KRW, implying the stock looks roughly 71.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 12,245 KRW (bear) to 23,183 KRW (bull), the price of 31,800 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

DNA Link Inc reported revenue of 19.3B KRW in FY2025 versus 23.0B KRW in FY2021, a compound −4.3%/yr. Reported net income was −16.4B KRW in FY2025.

Key figures

Market cap 1.2T KRW (≈ $839M) · P/S ratio 59.0 · Net margin −85.1% · Return on equity −26.3% · Return on assets (EBIT) −17.3% · Operating margin −200% · Revenue (TTM) 20.3B KRW · Revenue growth (YoY) +69.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 35% below its 52-week high and 98% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −42%, 127120 screens richer than that median.

Fair Value models

Bear 12,245 KRW Fair Value 18,548 KRW Bull 23,183 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 16,285 KRW 21,822 KRW 32,570 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 16,285 KRW 21,822 KRW 32,570 KRW 54

Open the full fair value analysis →

Notify me when 127120 reaches fair value

Put 127120 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 21/100

Of which business quality 27 · Market factors (momentum, volatility) 56

Profitability 1
Margins and returns on capital today
Quality Growth 63
Are margins and returns improving?
Cashflow 2
Earnings quality: real cash, not paper profit
Fin. Strength 88
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 50
Price trend over the last 3–12 months (market factor)
52W Momentum 74
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+21.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Start year 2020 (pandemic). Over 10 years: +7.4% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−69.1% (2020) → −63.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

127120 screens 71% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare DNA Link Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −43% · Above median
Profitability
Return on assets −9% · Above median
Net margin (TTM) −78% · Bottom 25%
Operating margin (TTM) −200% · Bottom 25%
Growth and dividend
Revenue growth 69% · Top 25%
Balance sheet
Debt / equity 0.07× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.04× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)96 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

DNA Link Inc · Fair Value
18,548 KRW −71%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "DNA Link Inc Fair Value". https://www.fairvalue-calculator.com/stock/127120

Frequently asked questions

Is DNA Link Inc (127120) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 18,548 KRW versus a price of 31,800 KRW, about −42% upside (overvalued).
What is the fair value of 127120?
Our model-based fair value for DNA Link Inc is 18,548 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 31,800 KRW.
What is the quality score of 127120?
DNA Link Inc has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DNA Link Inc (127120)?
Our model-based price target is the fair value of 18,548 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 12,245 KRW, optimistic scenario 23,183 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DNA Link Inc stock forecast for 2026?
Our models put fair value at 18,548 KRW, about −42% upside versus a price of 31,800 KRW (overvalued). Cautious scenario 12,245 KRW, optimistic scenario 23,183 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DNA Link Inc (127120)?
DNA Link Inc reported trailing-twelve-month revenue of about 20.3B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of DNA Link Inc (127120)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DNA Link Inc it is 18,548 KRW per share (as of Sep 24, 2026), against a price of 31,800 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is DNA Link Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 127120 trades above its calculated fair value: price 31,800 KRW, fair value 18,548 KRW, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 127120?
No. The price is what the market pays today (31,800 KRW); the fair value is what the company's own numbers justify (18,548 KRW). For DNA Link Inc the two are 13,252 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DNA Link Inc worth?
The market values DNA Link Inc at about 1.2T KRW (market capitalisation, as of Sep 24, 2026). Per share that is 31,800 KRW; our models calculate a fair value of 18,548 KRW per share.
What do the bullish and bearish scenarios say about 127120?
Our models span a range for DNA Link Inc: cautious scenario 12,245 KRW, base 18,548 KRW, optimistic 23,183 KRW per share (as of Sep 24, 2026, price 31,800 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DNA Link Inc (127120)?
Balance-sheet figures for DNA Link Inc (as of Sep 24, 2026): return on equity −26.3%, debt of 0.07 per unit of equity. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is 127120 from its 52-week high?
DNA Link Inc trades at 31,800 KRW, about 35% below its 52-week high of 48,900 KRW and 98% above the low of 16,050 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 18,548 KRW is for.
Which stocks are comparable to DNA Link Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DNA Link Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 31,800 KRW, calculated fair value 18,548 KRW (−42%), Quality Score 21/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 127120 calculated?
We run DNA Link Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 18,548 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. DNA Link Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DNA Link Inc (127120)?
The closing price on Sep 23, 2026 was 31,800 KRW. Our model-based fair value is 18,548 KRW, about −42% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DNA Link Inc right now?
The price sits above even our optimistic bull case (23,183 KRW). The favourable scenario is already priced in. Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (12,245 KRW to 23,183 KRW) leaves room in how you read the outcome.

Key figures of DNA Link Inc

How large is the market capitalisation of DNA Link Inc (127120)?
The market capitalisation of DNA Link Inc is 1.2T KRW (≈ $839M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DNA Link Inc (127120)?
The price-to-sales ratio of DNA Link Inc is 59.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of DNA Link Inc (127120)?
The net margin of DNA Link Inc is −85.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DNA Link Inc (127120)?
The return on equity (ROE) of DNA Link Inc is −26.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DNA Link Inc (127120)?
On an EBIT basis the return on assets of DNA Link Inc is −17.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DNA Link Inc (127120)?
The operating margin of DNA Link Inc is −200% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DNA Link Inc (127120)?
Revenue at DNA Link Inc is growing +69.4% versus a year earlier (3y avg +4.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does DNA Link Inc (127120) generate?
The free cash flow of DNA Link Inc is −53.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DNA Link Inc (127120) carry?
The net debt of DNA Link Inc is 2.1B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch DNA Link Inc in the live analysis

One click puts DNA Link Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.